Effector Therapeutics (NASDAQ: EFTR) might well be about to prove to us, once again, one of the basic lessons of investing in capital hungry pharmaceutical stocks. Yes, prices can be - are, hugely volatile. This is because there are certain valuations points along the way to a new drug being approved. Pass one of those and the company simply is, objectively, worth more. Therefore the stock price goes up. But it's also true that all of this work has to be funded with stockholder capital. Which leads to the idea that every step forward leads to a step back.
Think it through in a very simple manner. We have, say, four stages that a new drug or treatment must get through (Phases I, II and III trials, then FDA approval). It's much more than this but just for simplicity's sake. Failure at any one of these hurdles means real failure. All the money spent to that point has been wasted. Passing any one of the four tests buys the opportunity to go on and try to pass the next one. Add one more thing - until that FDA approval there is no asset here. Only hopes and dreams that there will be one. So, this is always funded by stockholder capital - no one will lend into such a plan.
But no one funds the whole process right at the start. Why would they? It's better to fund each stage separately. That is, pass a test then issue more stock to gain the capital to try to reach the next one. Apart from anything else passing a test increases the value of the company, that then means that less of the company must be sold in order to raise the capital needed. Capital is cheaper, that is.
Effector Therapeutics stock price from NASDAQSo, we've just had the news from Effector that one of their drug candidates is doing well in Phase II tests. Excellent, that's one of those valuation points, the stock price should - objectively - rise at this point. It's not so much that the test has been passed, it's that it hasn;t been failed. But now look at the accounts. There's about $20 million in cash and equivalents there. Losses run around $10 million a quarter. And the next stage is Phase III tests which really do cost money. So, we've a 6 month runway for the company without new capital. The corporate valuation has just risen as a result of passing the test.
We'd expect a capital raise real soon now. Which is, we think, why there's that volatility in the Effector stock price. Yes, the test passed, the company's worth more. But how much will they try to raise at what price?